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Summary 
U.S. soybean, cotton, and corn farmers have rapidly adopted genetically engineered (GE) 
varieties of these crops since their commercialization in the mid-1990s. Over the last decade, GE 
varieties in the United States have increased from 3.6 million acres to 143 million acres. 
Worldwide, 25 countries planted GE crops on approximately 309 million acres in 2008. GE 
varieties now dominate soybean, cotton, and corn production in the United States, and they 
continue to expand rapidly in other countries. As adoption has spread, policy debates have 
continued over the costs and benefits of GE products. 
Ongoing concerns include the impacts of GE crops on the environment and food safety, and 
whether GE foods should be specially labeled. Underlying these issues is the question of whether 
U.S. regulation and oversight of biotechnology—with responsibilities spread primarily among the 
U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the 
Environmental Protection Agency (EPA)—are adequate, particularly as newer applications, for 
example, biopharmaceuticals (drugs manufactured with the use of GE crops or animals) or 
stacked GE traits in single organisms, emerge that did not exist when the current regulatory 
regime was established. 
Regulatory noncompliance incidents most pointedly raise concerns about the adequacy of 
existing U.S. regulatory structures. About 16 major events have occurred since 1995, according to 
USDA’s Animal and Plant Health Inspection Service (APHIS). Another recurring concern has 
been the adequacy of APHIS’s environmental assessments (EAs) for deregulating GE plants. In 
2006, a U.S. district court held that USDA’s EA for a variety of GE alfalfa was inadequate for 
issuing a finding of no significant impact (FONSI); the court vacated APHIS’s decision to 
deregulate GE alfalfa and ordered APHIS to complete an environmental impact statement (EIS). 
The federal court subsequently enjoined further planting until the EIS was completed. In July 
2010, the Supreme Court overturned the federal court’s decision to enjoin planting. The final EIS 
is expected by the end of the year, but APHIS has not indicated an intent to allow planting under a 
“partial deregulation” in the interim. A similar case involves APHIS’s decision in 2005 to 
deregulate GE sugar beets on the basis of its EA. That decision was also challenged, and the 
federal court vacated the deregulation of the GE sugar beets and ordered APHIS to complete an 
EIS. In July 2010, the federal court declined to enjoin GE sugar beet planting, but in vacating 
APHIS’s decision to deregulate the GE beets, the court has effectively halted planting, except 
under regulated conditions. APHIS is currently evaluating a request to partially deregulate GE 
sugar beets for 2011. 
In October 2008, APHIS announced the first revision of its biotechnology regulations since their 
promulgation in 1987. Proposed changes include a multi-tiered permitting system, new risk 
categorizations for assessing environmental releases of GE organisms, regulation of GE plants 
that produce pharmaceutical and industrial compounds, and new standards for low-level presence 
of regulated GE products. A final rule on the proposed changes has not yet been published. Other 
recent issuances include FDA’s January 2009 final guidance on regulation of GE animals and 
products. APHIS is now seeking public comment and data concerning ongoing and future 
research on GE animals. In a ruling in January 2008, APHIS published its final guidance on the 
safety of meat and milk from cloned animals.  
Legislative activity in the 111th Congress was modest. Two bills (H.R. 5578 and H.R. 5579) were 
introduced by Representative Kucinich, who had introduced similar bills in previous years.  
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Adoption of Biotechnology in Agriculture1 
Farmers have always modified plants and animals to improve growth rates and yields, create 
varieties resistant to pests and diseases, and infuse special nutritional or handling characteristics. 
Such modifications have been achieved by crossbreeding plants and animals with desirable traits, 
through hybridization, and other methods. Now, using recombinant DNA techniques, scientists 
also genetically modify plants and animals by selecting individual genes that carry desirable traits 
(e.g., resistance to a pest or disease) from one organism, and inserting them into another, 
sometimes very different, organism, that can be raised for food, fiber, pharmaceutical, or 
industrial uses. 
Karl Ereky, a Hungarian engineer, coined the term “biotechnology” in 1919 to refer to the science 
and the methods that permit products to be produced from raw materials with the aid of living 
organisms.2 According to the Convention of Biological Diversity, biotechnology is “any 
technological application that uses biological systems, living organisms, or derivatives thereof, to 
make or modify products or processes for specific use” (Article 2). According to the FAO’s 
statement on biotechnology, “interpreted in a narrow sense, ... [biotechnology] covers a range of 
different technologies such as gene manipulation and gene transfer, DNA typing and cloning of 
plants and animals.”3 
Since genetically engineered (GE, sometimes called genetically modified organism or GMO) 
crop varieties first became commercially available in the mid-1990s, U.S. soybean, cotton, and 
corn farmers have rapidly adopted them in order to lower production costs and increase crop 
yields. Proponents point to the emergence of “second generation” GE commodities that could 
shift the focus of biotechnology from the “input” side (creating traits that benefit crop production, 
such as pest resistance) to the “output” side (creating traits that benefit consumers, such as lower-
fat oils). These second generation products could offer enhanced nutritional and processing 
qualities and also industrial and pharmaceutical uses. Future products are expected to be 
livestock- as well as crop-based. Critics, meanwhile, complain that biotechnology companies 
generally have not yet delivered the consumer benefits they have been promising for years. 
Incidents of regulatory noncompliance have continued to spike concern about the adequacy of 
regulatory structures. In December 2008, a small amount of unapproved GE cotton was harvested 
along with commercially available GE cotton. The unapproved GE cotton variety produces a 
pesticide that is a plant-incorporated protectant (PIP). In August 2006, traces of an unapproved 
variety of GE rice were reported in commercial rice samples from parts of the southern United 
States (see “GE Rice,” below). These incidents have added to the ongoing interest in a number of 
public policy questions. What are the environmental and food safety impacts of GE crops and 
animals? What obstacles and opportunities are exporters of GE crops encountering in the global 
marketplace? Is the current U.S. regulatory framework, which is based primarily upon statutory 
authorities enacted before the rise of agricultural biotechnology, adequate for these new 
technologies and products? 
                                                             
1
 Among the sources for this report are various materials by USDA’s Economic Research Service (ERS) and Animal 
and Plant Health Inspection Service (APHIS), the Pew Initiative on Food and Biotechnology, various issues of Food 
Chemical News, a weekly trade publication, and the Biotechnology Industry Organization (BIO). 
2
 OECD. Policy Brief, Modern Biotechnology and the OECD, June 1999. http://www.oecd.org/dataoecd/29/40/
1890904.pdf. 
3
 FAO. FAO Biotechnology Glossary, http://www.fao.org/biotech/index_glossary.asp. 
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Current Applications 
Crops 
In 2008, GE crops were planted on an estimated 308.8 million acres worldwide, a year-over-year 
increase of 26.4 million acres (Figure 1). The total number of countries growing such crops 
reached 25 in 2008. Most of the acreage was highly concentrated among four crops—soybeans, 
corn, cotton, and canola—and six countries. The United States has approximately 50% of global 
acreage (154.4 million acres), and Argentina had 16.8% (51.9 million acres). Brazil (12.6%, 39.0 
million acres), Canada (6.1%, 18.8 million acres), India (6.1%, 18.8 million acres), and China 
(3.0%, 9.4 million acres) have the largest shares of the remaining planted acres.4 
Figure 1. Global Acreage Planted to GE Crops, 1996-2009 
 
Source: International Service for the Acquisition of Agri-biotech Applications (ISAAA), Clive James, 2007 ISAAA 
Report on the Global Status of Biotech/GM Crops. Accessed July 2009 at http://www.isaaa.org/resources/
publications/briefs/37/executivesummary/default.html. 
In the United States, over 60 GE plant varieties were approved by APHIS for commercial use 
through early 2005.5 By 2009, 70 plant varieties had been deregulated by APHIS. Ninety-one 
percent of all U.S. soybean, 88% of all upland cotton, and 85% of all corn acres were planted 
with GE seed varieties in 2009, according to USDA’s National Agricultural Statistics Service 
(Figure 2, Table 1). Virtually all current commercial applications benefit the production side of 
agriculture, with weed and insect control by far the most widespread uses of GE crops in the 
United States and abroad. 
                                                             
4
 International Service for the Acquisition of Agri-biotech Applications (ISAAA), ISAAA Brief 39-2008, Executive 
Summary: The First Thirteen Years, 1996 to 2008 Report on the Global Status of Biotech/GM Crops. Accessed January 
2008 at http://www.isaaa.org/resources/publications/briefs/39/executivesummary/default.html 
5
 Sources: Information Systems for Biotechnology at Virginia Tech; also, USDA, ERS, The First Decade of 
Genetically Engineered Crops in the United States, April 2006, which can be accessed at http://www.ers.usda.gov/
Publications/eib11/. 
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Figure 2. Adoption of Genetically Engineered Crops in the United States, 1996-2009 
 
Source: USDA Economic Research Service 
Notes: Data for each crop includes more recently developed varieties engineered with both herbicide tolerance 
and pest resistance. These multiple trait plants are referred to as “stacked trait” varieties. 
Table 1. U.S. Acreage in Major GE Crops, 1996 and 2008-2009 
(acres in millions) 
 Soybeans Upland Cotton (UC) Corn 
 Acres % of all soy planted Acres % of all UC planted Acres % of all corn planted 
1996 4.2 7 2.2 17 2.9 4 
2008 68.6 92 7.7 86 69.9 80 
2009 77.5 91 7.8 88 73.9 85 
Source: USDA-NASS. Acreage Report, June 2009. 
Herbicide-tolerant (HT) crops are engineered to tolerate herbicides that would otherwise kill 
them along with the targeted weeds. These include HT soybeans, HT upland cotton, and to a 
lesser extent, HT corn. Many of these are referred to as “Roundup Ready” because they are 
engineered to resist Monsanto’s glyphosate herbicide, marketed under the brand name 
“Roundup.” More recently, Monsanto has announced various “stacked trait” varieties—varieties 
that combine resistance not only to glyphosate/Roundup but also to the herbicides dicamba and 
glufosinate. 
Insect-resistant crops effectively have the pesticide inserted into the plants themselves to control 
insect pests for the life of the crop. These varieties are often referred to as having a plant-
incorporated protectant (PIP). Many of these crops have been genetically engineered with Bt 
(Bacillus thuringiensis, a soil bacterium), which produces a naturally occurring pesticide.6 These 
                                                             
6
 Because Bt is a natural occurring pesticide, it can be used under certain conditions on organically produced plants. Its 
incorporation into GE commodities concerns some organic producers because of the risk of creating Bt tolerant pests 
(continued...) 
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insect-resistant varieties are most prevalent in upland cotton to control tobacco budworm, 
bollworm, and pink bollworm; and in corn to control earworm and several types of corn borers. 
Monsanto is also developing “stacked trait” varieties of soybeans and sugar cane that are resistant 
to insects as well as glyphosate/Roundup. 
Other crops approved for commercialization have included varieties of flax, papaya, potatoes, 
radicchio, rapeseed, rice, squash, sugar beets, tobacco, and tomatoes. However, these are either 
not commercialized or not widely planted. For example, the biotechnology firm Calgene’s 
FlavrSavr tomato, first marketed to consumers from 1995 to 1997, was withdrawn after Calgene 
determined that the varieties being grown were not of consistently high quality. GE potato 
varieties peaked several years ago at 2%-3% of the market; they were discontinued by the seed 
developer in 2001, mainly after several fast food and snack food companies declined to buy them. 
Varieties of GE wheat and rice, as well as flax and radicchio, have received regulatory approval 
but have not been commercially marketed (and/or research has been discontinued), presumably 
due largely to perceived producer or consumer unease with them. 
In contrast to abandoning certain approved GE products, a variety of white GE corn has recently 
begun to be used in tortilla making after initial resistance by food processors. Herbicide resistant 
GE sugar beets were only planted in large acreage in the 2008 crop year. While commercially 
available since 2000, Western beet growers did not plant them because sugar-using food 
companies (e.g., Hershey, Mars) and beet sugar industry groups (e.g., American Crystal Sugar) 
balked at the idea of GE beets, thinking that consumers would be opposed. That opposition—real 
or potential—has apparently subsided to the point that processors have cleared their growers to 
plant the GE variety.7 Nonetheless, the Center for Food Safety filed suit in January 2008 
challenging APHIS’s deregulation of GE sugar beets arguing that wind-pollinated GE sugar beets 
will inevitably cross-pollinate with related crops being grown in proximity, contaminating 
conventional sugar beets and organic chard and table beet crops.8 
Nonetheless, USDA reported that between 1987 and early 2005, APHIS had approved more than 
10,700 applications to conduct field tests of various GE crop varieties (out of 11,600 received 
from companies and other researchers), which the USDA characterized as “a useful indicator of 
R&D efforts on crop biotechnology.” Nearly 5,000 applications were approved for corn alone, 
followed by soybeans, potatoes, cotton, tomatoes, and wheat. More than 6,700 applications were 
for HT and insect resistant varieties; the others were to test product quality, virus or fungal 
resistance, or agronomic (e.g., drought resistance) properties.9 By October 2008, APHIS had 
approved more than 13,000 field trials of GE plants, most of which continued to be crop plants 
bearing genes conferring resistance to certain insects or tolerance to certain herbicides. 
                                                             
(...continued) 
thereby decreasing the utility of Bt to organic farming operations.  
7
 Some of the reduced public opposition to the GE beets may be based on the fact that sugar crystals do not contain any 
remnants of the GE modified protein and, thus, could pose no dietary risk.  
8
 The legal challenge seeking an injunction against was filed in the U.S. District Court for the Northern District of 
California and also includes the Sierra Club and the Organic Seed Alliance as plaintiffs. The court filing may be 
accessed at http://www.centerforfoodsafety.org/pubs/Final%20Complaint.pdf. 
9
 ERS, The First Decade of Genetically Engineered Crops in the United States. April, 2006. http://www.ers.usda.gov/
publications/eib11/eib11.pdf 
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Animal Products 
Fewer animal-based GE products are commercially available, notably excepting dairy production. 
Chymosin, a biotechnology-produced enzyme, is used widely in cheese production. Bovine 
somatotropin (BST, also known as “bovine growth hormone”) is a naturally occurring protein that 
can be produced in greater quantities through genetic engineering. The GE version of BST (rBST) 
was first approved by the U.S. Food and Drug Administration (FDA) in 1993. Reports suggest 
that more than 30% of all U.S. dairy cows are administered BST to boost milk production (by an 
estimated 10%-15%).10 Several other emerging animal biotechnologies, while not yet 
commercialized, are believed by researchers to hold great promise (see “Future GE Applications,” 
below).11 In February 2009, FDA approved the first product from a transgenic animal, an anti-
clotting protein derived from the milk of transgenic goats.12 The animals are genetically 
engineered to produce a recombinant human antithrombin III protein in their milk.13 A 
Netherlands-based biotechnology firm also announced plans to seek U.S. and European approval 
in 2009 for Rhucin, made from a human protein purified from the milk of genetically engineered 
rabbits. The protein, C1 esterase inhibitor, helps control inflammation. 
U.S. Food Products Containing GE Crops14 
An estimated 70% of all processed U.S. foods likely contain some GE material. That is largely 
because two such plants (corn and soybeans, where farmers have widely adopted GE varieties) 
are used in many different processed foods. U.S. biotechnology rules do not require segregation 
and labeling of GE crops and foods, as long as they are substantially equivalent to those produced 
by more conventional methods (see “Regulation and Oversight,” below). 
Soy-based ingredients include oil, flour, lecithin, and protein extracts. Corn-based ingredients 
include corn meal and corn syrups, used in many processed products. Canola oil (mostly imported 
from Canada, where GE-canola is grown) and cottonseed oil are used in cooking oils, salad 
dressings, snack foods, and other supermarket items. No GE-produced animals are yet approved 
for human consumption, although cheeses may contain chymosin, and dairy products may have 
been produced from milk containing GE-BST. 
As noted earlier, because most other government-approved GE crops are not being grown 
commercially, few other GE-derived foods are reaching consumers. 
                                                             
10
 Milk containing rBST may be falling out of favor in some places. Wal-Mart, the largest grocery retail outlet in the 
United States, has a private label milk (Great Value Milk) that will be rBST free. Kroger completed a phase-out of 
rBST milk in February 2008. Safeway switched to rBST free milk in its private line, although it continues to sell other 
rBST milk. Starbucks began using only rBST free milk in January 2008.  
11
 Also see CRS Report RL33334, Biotechnology in Animal Agriculture: Status and Current Issues, by Tadlock 
Cowan. 
12
 “FDA approves drug product from transgenic goats.” Food Chemical News, February 9, 2009. 
13
 In September 2008, APHIS announced a request for public comment and technical empirical data concerning 
ongoing and future research on genetically engineered animals. 
14
 Sources include Cornell University, Genetically Engineered Organisms Public Issues Education Project (GEO-PIE), 
at http://www.geo-pie.cornell.edu/crops/eating.html, accessed on February 3, 2009; USDA, APHIS, Petitions of 
Nonregulated Status Granted or Pending by APHIS, at http://www.aphis.usda.gov/brs/not_reg.html and Colorado State 
University, Transgenic Crops: An Introduction and Resource Guide. The latter report is available at 
http://www.colostate.edu/programs/lifesciences/TransgenicCrops/index.html. The site is not regularly maintained but 
archived materials are available through 2004. 
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Analysts say some farmers are wary of planting GE crop varieties because their customers may 
be worried about their safety, although as the case of sugar beets noted above suggests, public 
opposition to GE products in processed food may be declining. Biotechnology supporters contend 
that safety concerns are unfounded because scientific reviews have found approved GE crop 
varieties to be safe, and that foreign governments are simply using such concerns to maintain 
barriers to imports. 
Future GE Applications15 
“Input” Traits 
For farmers, new insect-resistant and herbicide-tolerant GE varieties are under development or 
have been developed for other crops besides corn, cotton, and soybeans. These include wheat and 
rice (see below), alfalfa, peanuts, sunflowers, forestry products, sugarcane, apples, bananas, 
lettuce, strawberries, and eventually other fruits and vegetables. Other traits being developed 
through genetic engineering include drought and frost tolerance, enhanced photosynthesis, and 
more efficient use of nitrogen. Tomatoes that can be grown in salty soils, and recreational turf 
grasses that are herbicide tolerant, pest resistant, and/or more heat and drought tolerant, also are 
under development. In animal agriculture, pigs have been engineered for increased sow milk 
output to produce faster-growing piglets. Cloned cattle also have been developed to resist 
mastitis. APHIS approved field trials in June 2007 for a transgenic sunflower with a carp growth 
hormone inserted. The GE sunflower would be used in aquaculture feed for farm raised shrimp. 
Currently awaiting government approval for food use are GE salmon that require as little as half 
the usual time to grow to market size. Other such fish could follow later.16 
“Output” Traits 
For processors and consumers, research on a range of GE products is continuing: oilseeds low in 
saturated and transfats; tomatoes with anti-cancer agents; grains with optimal levels of amino 
acids; rice with elevated iron levels; and rice with beta-carotene, a precursor of Vitamin A 
(“golden” rice). Other future products could include “low-calorie” sugar beets; strawberries and 
corn with higher sugar content to improve flavor; colored cotton; improved cotton fiber; delayed-
ripening melons, bananas, strawberries, raspberries, and other produce (delayed-ripening 
tomatoes already are approved); and naturally decaffeinated coffee. Critics, however, point out 
that, although biotechnology advocates have been forecasting the adoption of various “output” 
traits for some time, few have actually reached the marketplace. 
Other plants being developed could become “factories” for pharmaceutical compounds. The 
compounds would be extracted and purified for human and animal health uses (among concerns 
                                                             
15
 Sources include “Review of Agricultural Biotechnology,” hearing before the Subcommittee on Conservation, Credit, 
Rural Development, and Research of the U.S. House Committee on Agriculture, June 23, 2004 (Serial No. 108-34); 
BIO; Colorado State University; and ERS, Economic Issues in Agricultural Biotechnology (AIB-762), February 2001 
(table, p. 19), at http://www.ers.usda.gov/publications/aib762/; and The First Decade of Genetically Engineered Crops 
in the United States. 
16
 So far one GE fish, the “Glofish,” has been marketed in the United States. It is an aquarium fish that is not approved 
for consumption. For more on genetically engineered fish, see CRS Report RL32974, Genetically Engineered Fish and 
Seafood, by Rachel Borgatti and Eugene H. Buck. 
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are whether they could “contaminate” food crops; see “Plant-Based Pharmaceuticals from 
Biotechnology,” below). Some varieties of plants under development could also produce 
“bioindustrials,” including plastics and polyurethane. Future transgenic livestock also might yield 
pharmaceuticals and/or human organ and tissue replacements. To date, none of these innovations 
have been commercialized, although some have begun field trials. 
Regulation and Oversight 
Coordinated Framework for Regulation of Biotechnology 
The basic federal guidance for regulating biotechnology products is the Coordinated Framework 
for Regulation of Biotechnology (51 Fed. Reg. 23302), published in 1986 by the White House 
Office of Science and Technology Policy (OSTP). A key regulatory principle is that genetically 
engineered products should continue to be regulated according to their characteristics and unique 
features, not their production method—that is, whether or not they were created through 
biotechnology. The framework provides a regulatory approach intended to ensure the safety of 
biotechnology research and products, using existing statutory authority and previous agency 
experience with traditional breeding techniques. The three lead agencies are USDA’s Animal and 
Plant Health Inspection Service (APHIS), the Food and Drug Administration (FDA) at the 
Department of Health and Human Services, and the Environmental Protection Agency (EPA). 
Animal and Plant Health Inspection Service 
APHIS regulates the importation, interstate movement, and field testing of GE plants and 
organisms that are or might be plant pests under the Plant Protection Act (PPA; 7 U.S.C. §7701 et 
seq.). APHIS regulates animal biologics (i.e., viruses, serums, toxins for animal vaccines) under 
the Virus, Serum, and Toxins Act (21 U.S.C. 151 et seq.). Specifically, GE plants that are or might 
be plant pests are considered “regulated articles” under APHIS regulations (7 CFR 340-340.9). 
APHIS authorization must be obtained prior to import, interstate movement, or environmental 
release, including field testing. 
More specifically, a “regulated” plant cannot be introduced into the environment, or even field 
tested, unless its developer obtains APHIS authorization through either the (1) permit process or 
(2) notification process. Permits impose restrictions on movement and planting to prevent escape 
of plant material that may pose a pest risk. Sponsors follow APHIS guidance on testing and 
movements to ensure that the plant will not damage agriculture, human health, or the 
environment. Plant-based pharmaceuticals virtually always must be developed under the permit 
process. However, most other GE crops have been developed under the notification option, an 
expedited procedure that is less rigorous than permitting. Notification can be used in lieu of 
permitting when the plant species is not considered a noxious weed (or weed in the release area) 
and other APHIS standards are met. 
Regardless of the process chosen, after testing is completed, a developer next seeks “non-
regulated status” from APHIS, the typical route to full commercialization and no further formal 
oversight. The developer must provide APHIS with extensive information on plant biology and 
genetics, and potential environmental and plant pest impacts that may result from the 
modification. APHIS conducts a formal environmental assessment (EA) and has public comment 
periods before deciding whether to approve the developer’s request for “non-regulated status.” 
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Food and Drug Administration (FDA) 
FDA regulates food, animal feed additives, and human and animal drugs, including those from 
biotechnology, primarily to ensure that they pose no human health risks, mainly under the Federal 
Food, Drug and Cosmetic Act (FFDCA; 21 U.S.C. §301 et seq.) and the Public Health Service 
Act (42 U.S.C. §201 et seq.). Under the FFDCA, all food and feed manufacturers must ensure 
that the domestic and imported products they market are safe and properly labeled. All domestic 
and imported foods and feeds, whether or not they are derived from GE crops, must meet the 
same standards. Any food additive, including any introduced through biotechnology, cannot be 
marketed before it receives FDA approval. However, additives that have been determined to be 
“generally recognized as safe” (GRAS) do not need such preapproval. 
To help sponsors of foods and feeds derived from GE crops comply, FDA encourages them to 
participate in its voluntary consultation process. All GE-derived products now on the U.S. market 
have undergone this process. With one exception, none of these foods and feeds were considered 
to contain a food additive, so they did not require approval prior to marketing. However, a May 
1992 FDA policy statement noted that GE foods must undergo a special review under certain 
conditions, such as if the gene transfer produces unexpected genetic effects, changes nutrients or 
toxicant levels from the food’s traditional variety, might contain an allergen from another crop, or 
would be used to host an industrial or pharmaceutical substance, for example.17 
In June 2006, FDA published new guidance under which developers of new plant varieties 
intended for food use—including those that are bioengineered—can provide FDA with any 
information about new proteins they are using in the early stages of crop development. This 
voluntary consultation is to occur prior to the stage of development where the new proteins might 
“inadvertently” enter the food supply. FDA believes that any potential risk from the low-level 
presence of such material in the food supply would be limited to the remote possibility of it 
containing or consisting of a new protein that might be an allergen or toxin.18 
On January 15, 2009, the U.S. Food and Drug Administration (FDA) released final guidance on 
how it is to regulate GE animals and products. FDA is to do so under its existing statutory 
authority and regulations. Generally, GE-derived foods, for example, are to be regulated like non-
GE foods; if their composition does not differ from their conventional counterparts, they will not 
have to be labeled. Nonetheless, developers of GE animals and of GE-derived products must gain 
FDA pre-market approval. 
Although animal biotechnology involves many techniques other than cloning, this latter 
technology has attracted widespread attention. A final risk assessment and industry guidance on 
the safety of meat and milk from cloned cattle, pigs, and goats and their offspring were released 
January 15, 2008, by FDA. The documents generally echoed FDA’s December 28, 2006, draft 
risk assessment, which found that such products are as safe to eat as those of conventionally bred 
animals. The FDA also concluded that cloning poses the same risks to animal health as those 
found in animals created through other assisted reproductive technologies—although the 
frequency of such problems is higher in cloning. (Scientists stress that cloning is an assisted 
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 See the FDA biotechnology website at http://www.cfsan.fda.gov/~lrd/biocon.html#policy. 
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 FDA’s Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New 
Plant Varieties Intended for Food Use can be accessed at http://www.cfsan.fda.gov/~dms/bioprgu2.html. The guidance 
was issued in draft form in November 2004 and had earlier been proposed by OSTP in 2002. 
Agricultural Biotechnology: Background and Recent Issues 
 
Congressional Research Service 9 
reproduction technique that does not involve any transfer or alteration of genes through GE.) The 
agency said it was no longer asking industry to refrain voluntarily from marketing the products of 
cloned animals and their offspring, although the U.S. Department of Agriculture (USDA) did ask 
that it be continued for products from clones (but not from the offspring of clones).19 
Environmental Protection Agency (EPA) 
EPA must approve the use of all pesticides, including those genetically engineered into plants, 
which it terms “plant-incorporated protectants” (PIPs). EPA essentially determines a PIP’s 
environmental safety through its authority under the Federal Insecticide, Fungicide, and 
Rodenticide Act (FIFRA; 7 U.S.C. §136 et seq.). Also, under the FFDCA, the EPA establishes 
tolerances (i.e., safe levels) for pesticides in foods. Pre-commercial regulation is through a system 
of notifications for small-scale field tests or experimental use permits for larger field tests. As for 
any pesticide, EPA requires the manufacturer of a PIP to obtain a registration through a regulatory 
process intended to ensure its safe use environmentally. 
In practice, all three agencies have more detailed procedures than described here for monitoring 
and approving the development and commercialization of GE crops and foods, particularly if they 
are for new uses (e.g., pharmaceuticals). However, the fundamental guiding policy assumption 
since 1986 has been that the biotechnology process poses no unique or special risks; therefore it 
demands no new laws beyond those that already govern the health, safety, efficacy, and 
environmental impacts of more traditional production methods. 
Assessments of Current Policy 
The biotechnology industry, prominent U.S. agricultural groups, and many scientific authorities 
continue to subscribe to the current coordinated framework described above. They cite various 
studies in asserting that there is no evidence that current GE crops have harmed the environment 
or human health.20 
These reports generally conclude that current GE crops likely pose no greater risks than 
conventional varieties, that each GE product should be assessed on a case-by-case basis, and that 
the current U.S. regulatory framework is adequate. However, the reports have also suggested a 
number of administrative or regulatory changes that might be adopted to improve oversight. 
Critics, including some consumer and environmental groups, have gone further, raising questions 
about whether the current laws themselves remain adequate to protect human health and the 
environment, particularly as emerging GE applications—such as plant-based pharmaceuticals and 
industrial compounds, and transgenic animals, including insects—increasingly challenge the 
agencies’ regulatory capabilities. They see gaps in the existing pre-market approval processes, 
                                                             
19
 See CRS Report RL33334, Biotechnology in Animal Agriculture: Status and Current Issues, by Tadlock Cowan. 
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 These studies include the Institute of Medicine/National Research Council 2004 report Safety of Genetically 
Engineered Foods: Approaches to Assessing Unintended Health Effects; the National Academy of Sciences/National 
Research Council (NAS/NRC) 2002 report Environmental Effects of Transgenic Plants: The Scope and Adequacy of 
Regulation; the NAS/NRC 2000 report Genetically Modified Pest-Protected Plants: Science and Regulation; the 
Council for Agricultural Science and Technology (CAST) 2001 report Evaluation of the U.S. Regulatory Process for 
Crops Developed Through Biotechnology; and the CAST 2002 report Comparative Environmental Impacts of 
Biotechnology-derived and Traditional Soybean, Corn, and Cotton Crops. 
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and in post-market oversight of GE crops, that they contend may expose humans and the 
environment to unwarranted risks. These critics have argued that new legislation is needed to 
clarify agency roles and strengthen their regulatory authority, particularly over future novel GE 
applications. 
A number of agricultural organizations, while not necessarily clamoring for new laws, have 
expressed wariness about some new biotechnology products now awaiting approval. Among other 
concerns, they worry about consumer acceptance, potential difficulties exporting these varieties 
to countries demanding the segregation and labeling of GMOs (or outright prohibition of GMOs), 
and the potential for inadvertently mixing GE with non-GE crops. The 2006 discovery of an 
unapproved variety of GE rice in commercial U.S. rice supplies, and the 2008 discovery of an 
unapproved GE cotton variety harvested with an approved variety, are indicative of the problem. 
Another court case involving the deregulation of Monsanto’s GE alfalfa also raised important 
concerns about the adequacy of APHIS regulatory regime. In May 2007, U.S. District Court for 
the Northern District of California in San Francisco held that APHIS had failed to properly 
consider the environmental effects of the GE alfalfa in granting approval.21 A coalition of farmers, 
consumers, and environmentalists, led by the Center for Food Safety, filed suit in 2006 alleging 
that GE alfalfa could create “super weeds” resistant to herbicide, hurt production of organic dairy 
and beef products, and cause farmers to lose export business due to risks of contamination to 
natural and organic alfalfa. Perhaps more than some other GE varieties, the GE alfalfa case raised 
important issues about the limitations of coexistence between traditional and GE production 
methods. The issue of whether gene flow from GE alfalfa could permanently harm growers who 
did not want to adopt GE varieties case was particularly clear in this case.22 
USDA Advisory Committee Report 
In late August 2006, USDA released a long-awaited status report by its Advisory Committee on 
Biotechnology and 21st Century Agriculture (AC21). The report covered biotech adoption and 
regulation, and included a discussion of the many outstanding policy issues. The AC21 report 
observed, for example, that “U.S. regulations are evolving slowly and many governing statutes 
were written before modern agricultural biotechnology was developed. That system may not be 
optimal to meet the needs of producers and consumers.”23 
Although all the AC21 members agreed on the importance of ensuring the food and feed safety of 
transgenic crops, they had differing views “about whether the current FDA regulatory system for 
transgenic crops was adequate to ensure safety and public acceptance.” Among other 
observations, the AC21 cited the lack of a “clear, comprehensive federal regulatory system to 
assess the environmental and food safety of transgenic animals before they are commercialized.” 
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 In January 2008, APHIS announced the preparation of an environmental impact statement on GE alfalfa. See Federal 
Register, Vol. 73, No. 4, January 7, 2008: 1198-1200 
22
 For a discussion of the technical issues in growing GE alfalfa in proximity to non-GE alfalfa, see the following 
University of California-Davis study: http://alfalfa.ucdavis.edu/2007AlfalfaConference/2007/07-96.pdf. 
23
 USDA Advisory Committee on Biotechnology and 21st Century Agriculture. Opportunities and Challenges in 
Agricultural Biotechnology: The Decade Ahead. July 13, 2006. The committee consists of biotech industry, 
agricultural, consumer and scientific representatives. Accessed January 2009 at http://www.usda.gov/wps/portal/!ut/p/
_s.7_0_A/7_0_1OB?contentidonly=true&contentid=AC21Reports.xml. 
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All sides of the debate, however, continue to agree that whatever policy course is pursued in the 
future, it should provide for a clear, predictable, trusted regulatory process.24 
Views on the FDA Guidance 
The recent FDA guidance on early food safety evaluations for new plant varieties (issued in June 
2006; see page 8) is widely viewed as that agency’s current policy thinking on AP. The 
Biotechnology Industry Organization (BIO) supported the FDA guidance, noting that it “provides 
safety assurance, while also recognizing the fact that ‘adventitious presence’ is a natural part of 
plant biology, seed production, and the distribution of commodity crops.” Several food industry 
officials also characterized the guidance as an important step toward a science-based policy 
regarding AP. However, critics such as the Center for Food Safety (CFS), a food safety and 
environmental advocacy organization, have complained that the guidance will more likely 
encourage “contamination” of the food supply by GE varieties rather than improve safety 
oversight. Moreover, the policy does not attempt to define or quantify an acceptable level, or 
levels, of AP.25 
In 2006, CFS sued FDA for allegedly failing to adopt any pre-market safety requirements for GE 
foods, or to require labels identifying foods containing GE material. The lawsuit sought the 
establishment of a mandatory, pre-market review system for all such foods.26 The case was 
subsequently dropped by agreement with the parties. 
APHIS Oversight 
USDA’s APHIS has taken a number of actions over the past several years intended to improve 
regulatory oversight (like FDA, utilizing its current legislative authorities). These have included 
consolidation of its activities under a new Biotechnology Regulatory Services (BRS) office; 
development of a compliance and enforcement unit to ensure GE developers’ adherence to the 
rules, and the publication of more stringent permit conditions for GE-derived plants for 
pharmaceuticals and industrials (see “Plant-Based Pharmaceuticals from Biotechnology,” below). 
In the January 23, 2004, Federal Register, the agency published a notice of its intent to prepare an 
environmental impact statement (EIS) evaluating these regulations, and requesting public 
comment on a number of possible changes. These include whether to broaden APHIS’s regulatory 
scope to cover GE plants that may pose a noxious weed risk or may be used as biological control 
agents; whether to establish new categories for field testing that delineate requirements based 
upon relative levels of potential risk; and whether to change (i.e., strengthen) its environmental 
reviews and permit conditions for GE plants producing pharmaceuticals and industrials. APHIS 
also solicited comments on ways that it might ease its requirements for lower-risk products. The 
agency received over 3,000 comments on its proposal. 
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 The various arguments are explored in more depth in an April 2004 Pew Initiative report, Issues in the Regulation of 
Genetically Engineered Plants and Animals. See http://pewagbiotech.org/. 
25
 As reported in “FDA issues ‘adventitious presence guidance for biotech plants,” in Food Chemical News, June 26, 
2006. See page 17 for additional discussion of the AP issue. 
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 A copy of the lawsuit and an accompanying press release can be viewed at the CFS website at 
http://www.centerforfoodsafety.org/Ge_Foods_FDA_Complaint6_7_2006.cfm. 
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OIG Criticisms 
In a December 2005 audit report, USDA’s Office of Inspector General (OIG) criticized APHIS’s 
biotech regulation. Noting the approval, at that point, of more than 10,600 applications for GE 
tests at more than 49,300 field sites, the OIG expressed concern that “the Department’s efforts to 
regulate those crops have not kept pace.” Various weaknesses in the approval and inspection 
process “increase the risk that regulated genetically engineered organisms will inadvertently 
persist in the environment before they are deemed safe to grow without regulation,” the report 
observed.27 
More specifically, the OIG stated that APHIS lacked basic information about the field test sites 
that it has approved, including their precise locations; and about what becomes of the crops—
including those tested for pharmaceutical or industrial uses—after testing ends. Where 
notifications (rather than permits) were used, APHIS did not review applicants’ containment 
protocols. Among other things, the OIG noted that APHIS site inspection requirements were 
vague and not always fulfilled by inspectors, and that the agency’s guidance for containing GE 
crops and seeds needed strengthening. 
Responding to the audit report, APHIS stated that most of the OIG recommendations “reaffirm 
APHIS’ decision to create the new Biotechnology Regulatory Service (BRS) and devote greater 
resources toward regulating biotechnology. Most of the recommendations are in line with changes 
that BRS has already enforced, is currently undertaking, or plans to implement.”28 
In January 2009, the OIG released another report concluding that the department did not have an 
import control policy to regulate GE animals and that its import policy for GE crops could 
become outdated as other countries increase the number of biotechnology products.29 
APHIS Regulatory Changes 
In July 2007, APHIS published a draft environmental impact statement (EIS) as part of the 
evaluation of its regulatory structure. In October 2008, APHIS proposed a revision of its 
regulations regarding the importation, interstate movement, and environmental release of certain 
GE organisms.30 The public comment period initially was to end on November 24, 2008, but was 
extended to June 29, 2009. A subsequent issue-focused meeting on the proposed rule changes was 
held on April 29-30, 2009. The final rule has not yet been published. These proposed revisions are 
the first since the regulations were established in 1987. Under current regulations, a GE organism 
is a regulated article if it is a plant pest or there is reason to believe it might become a plant pest. 
In the notification of the proposed regulation revisions, APHIS stated that technological advances 
have led to the possibility of developing GE organisms that do not fit within the plant pest 
definition, but still might cause environmental or other physical harm by the definition of a plant 
pest under the Plant Protection Act. According to APHIS, the new regulations would subject a GE 
                                                             
27
 USDA, OIG. Animal and Plant Health Inspection Service Controls Over Issuance of Genetically Engineered 
Organism Release Permits, accessed January 2009 at http://www.usda.gov/oig/webdocs/50601-08-TE.pdf. 
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 “BRS OIG Report Frequently Ask Questions,” which responds in more detail to the OIG criticisms. It can be viewed 
at http://www.aphis.usda.gov/brs/brs_oig.html. 
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 USDA, Office of the Inspector General, Southwest Region, USDA Controls Over Importation of Transgenic Plants 
and Animals, Report No. 50601-17-Te, December 2008.  
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 Federal Register. Vol. 73, No. 197, 60009-60048, October 9, 2008. 
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organism to oversight based upon known plant pest and noxious weed risks of the parent 
organisms, or based upon the traits of the GE organism, or based upon the possibility of unknown 
risks as a plant pest or noxious weed when insufficient information is available.31 The proposed 
regulations also include regulating GE seedlings, tubers, cuttings, bulbs, spores, etc. 
APHIS further proposes to reorganize the regulations for permit applications and evaluation 
procedures by discontinuing its notification procedure, while retaining the permitting procedure. 
The proposed regulations would also establish a new petition procedure for APHIS to approve a 
new conditional exemption from the permit requirements, which is currently done by amending 
regulations. 
For environmental releases, APHIS proposes a permitting system based on two primary risk-
related factors: (1) the ability of the unmodified recipient plant species to persist in the wild and 
(2) the potential of the GE trait to cause harm based on the plant pest and noxious weed 
definitions. With respect to the persistence factor, APHIS proposes grouping plant species into 
four risk categories based on the risk of persistence of the plant or its progeny in the environment 
without human intervention. Four similar risk categories are also proposed for potential harm 
caused by the GE trait. Other proposed regulatory changes include remediation authorities for 
failure to comply with regulations and agency response to low-level presence (LLP) of regulated 
plant materials in commercial seeds or grain that may be used for food or feed. 
Reactions to the proposed revisions were mixed, and were, in part, the reason APHIS extended 
the original comment period and held public meetings on some of the more controversial 
proposed changes (e.g., scope of the regulatory changes, incorporation of the Plant Protection 
Act’s noxious weed authority into APHIS’s regulatory authority, revision of the permit process, 
and environmental release of GE crops that produce pharmaceutical and industrial compounds). 
In their comments on the proposed rule changes, biotechnology industry representatives and 
nongovernmental organizations expressed opposition to the expansion of APHIS authority to 
regulate GE organisms if they posed a risk as a plant pest or noxious weed. The industry 
representatives also took issue with the with the proposal to take a voluntary approach to GE 
regulation, arguing that it could have a significant impact on international trade.32 The Center for 
Food Safety (CFS) denounced the proposal, stating that “these proposed regulations may set in 
motion a process that would put many GE crops completely beyond the bounds of regulation.” 
CFS said that its biggest concern is that the proposed rules remove established criteria in 
determining the very scope of regulation. In a similar response, the Union of Concerned Scientists 
denounced the proposed rules for failing to adequately protect the U.S. food supply from potential 
contamination from biopharm crops through cross-pollination or seed mixing between biopharm 
food crops and those food crops intended for consumption.33 In March 2009, more than 80 
advocacy groups signed a letter urging Secretary of Agriculture Tom Vilsack to halt approving 
GE crops until the agency changes its regulatory approach to biotechnology. 
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 Only a small fraction of weeds are considered to be noxious weeds. APHIS currently lists 98 aquatic, terrestrial, or 
parasitic plant taxa as noxious weeds. 
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 “Industry, NGOs, strongly oppose proposed USDA biotech regulation.” Inside U.S. Trade, October 17, 2008. .  
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 Food Chemical News. “USDA Proposed Biotech Regulatory Overhaul to Mixed Reviews,” vol. 50, no. 34, October 
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The National Environmental Protection Act and 
APHIS 
After a GE variety is approved for release into the environment on a test basis, the owner of the 
GE seed generally petitions APHIS for “deregulated status” of the particular GE “event” that has 
been approved. This is the last step to full-scale commercialization of the GE plant. Once the GE 
plant is deregulated, it is no longer subject to APHIS regulation under 7 C.F.R. Part 340. A 
significant step in the deregulation process involves an assessment of the plant’s environmental 
impact. The National Environmental Policy Act (NEPA) requires federal agencies to prepare a 
detailed Environmental Impact Statement (EIS) for all “major Federal actions significantly 
affecting the quality of the human environment.” The regulations governing the finding of a 
significant effect are promulgated by the Council on Environmental Quality (CEQ). When an EIS 
is not categorically required, an agency may determine, from the data already at hand, that the 
environmental impacts are not significant enough to warrant an EIS. This judgment permits the 
agency initially to prepare an Environmental Assessment (EA) rather than the lengthier and more 
detailed EIS. An EA is a public document that briefly provides the basis for determining whether 
to move forward with an EIS or to make a finding of no significant impact (FONSI). 
Several cases over the past five years have raised issues about the adequacy of APHIS’s 
regulatory structure in moving to deregulate a GE plant. APHIS on several occasions has issued a 
FONSI on the basis of an EA and deregulated a GE plant, only to have that decision decisively 
challenged in court. 
GE Alfalfa 
A U.S. District Court held in February 2007 that APHIS failed to properly consider the 
environmental effects of Monsanto’s GE alfalfa. The court vacated APHIS’s June 2005 decision 
deregulating GE alfalfa on the basis of an EA. In March 2007, the District Court of the Northern 
District of California issued a preliminary injunction, and in May 2007 the court issued a 
permanent injunction against planting or selling Monsanto’s line of GE alfalfa until a final EIS 
was prepared. In June 2009, the Ninth Circuit Court of Appeals affirmed the illegality of APHIS’s 
approval of deregulated status for Monsanto’s GE alfalfa. 
Not only did the GE alfalfa have environmental implications for domestic producers, the suit, 
brought by a coalition of farmers and the Center for Food Safety, also cited the concerns of 
farmers who sell to export markets.34 Japan and South Korea, America’s most important alfalfa 
customers, have warned that they will discontinue imports of U.S. alfalfa if a GE variety is grown 
in this country. U.S. alfalfa exports total nearly $480 million per year, with about 75% going to 
Japan. The court disagreed with USDA’s assertion that exports to Japan would not be harmed by 
the deregulation of GE alfalfa. 
On January 12, 2010, APHIS announced that the draft environmental impact statement 
concerning Monsanto and Forage Genetics International lines of GE alfalfa was available for 
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public comment.35 A series of public meetings in several cities was also held on February 3, 4, 
and 9, 2010. After a three-week extension for comments, the comment period ended March 3, 
2010. The final EIS, which will address the nearly 135,000 comments received, is expected to be 
published before the end of the year. APHIS has stated that the EIS will be completed in time for 
spring 2011 planting. 
The court’s decision to enjoin planting GE alfalfa until the final EIS was published was appealed 
to the Supreme Court.36 The Court agreed to hear that case on January 15, 2010, and on April 27, 
2010, the Court heard oral arguments. Monsanto’s appeal concerned whether the federal courts in 
the Ninth Circuit properly applied and interpreted the injunction standard in NEPA cases when 
they permanently enjoined planting until the EIS was complete. On June 21, 2010, in a 7-1 
opinion written by Justice Alito, the Supreme Court reversed the injunction, saying that the Ninth 
Court had overreached itself procedurally in halting the plantings. As of late August 2010, APHIS 
has not announced any intention to re-authorize the restricted plantings. Were APHIS to do so, 
any planting of GE alfalfa would have to be done under a rule for “partial deregulation,” a 
modification of existing planting restrictions for regulated organisms, perhaps limiting planting to 
specific geographic areas under controlled procedures. Such a partial deregulation, however, 
could trigger the need for a new EA on the impact of partial deregulation.  
GE Sugar Beets 
In February 2005, APHIS issued a finding of no significant impact on the environment (FONSI) 
for the cultivation and agricultural use of a Monsanto-developed variety of glyphosate-tolerant 
sugar beet (Event H7-1).37 The ruling meant that GE beets were no longer a regulated article 
under 7 C.F.R. Part 340. The GE beets were first planted in the western United States in spring 
2008. Similar to the response to APHIS’s FONSI regarding GE alfalfa, a case was filed in U.S. 
District Court for the Northern District of California by the Center for Food Safety and 
Earthjustice in January 2008 representing a coalition of farmers and consumers.38 As with the 
alfalfa case, the plaintiffs claimed that APHIS had violated NEPA by not conducting an EIS 
before granting the GE beets unregulated status. 
Sugar beet seed is grown primarily in Oregon’s Willamette Valley. The area is also an important 
seed growing area for crops closely related to sugar beet (e.g., chard and table beets). Sugar beets, 
like alfalfa, are wind pollinated. Eventually, GE beets would cross-pollinate with related crops. 
This would have significant economic impacts on organic producers of Swiss chard and table 
beets being grown in the same areas as the GE beets. In his September 2009 order requiring 
APHIS to prepare an EIS, the presiding judge determined that “the potential elimination of a 
farmer’s choice to grow non-genetically engineered crops, or a consumer’s choice to eat non-
genetically engineered food, [is] an action that potentially eliminates or reduces the availability of 
a particular plant [and] has a significant effect on the human environment.” The court concluded 
that there was no support in the record for APHIS’s conclusion of no significant impact. 
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At a meeting in December 2009, the U.S. District Court for the Northern District of California set 
out a schedule and process for determining the remedies regarding the sugar beets. The process 
did not interfere with the planting of the beets in 2010. Oral arguments were heard on June 11, 
2010. On August 13, 2010, the court revisited the issue of whether to issue an injunction, as had 
been done with GE alfalfa. Given that the Supreme Court had just ruled that the injunction for GE 
alfalfa was improper, the Ninth Court vacated APHIS’s deregulation decision without enjoining 
planting. While avoiding the “drastic remedy,” as the Supreme Court described the injunction of 
GE alfalfa, the practical effect of vacating APHIS’s GE sugar beet deregulation decision is that 
planting GE sugar beet is now effectively halted. Because nearly 95% of sugar beets planted in 
2009/2010 are the GE variety, this raises questions about the availability of non-GE sugar beet 
seed for the 2011 planting season. 
GE Ethanol Corn 
In June 2009, APHIS filed a request for additional comments on a petition by Syngenta Seeds, 
Inc. to deregulate Alpha-Amylase Maize Event 3272.39 This GE variety of corn produces a 
microbial enzyme that facilitates ethanol production. APHIS has prepared a draft EA and plant 
pest risk assessment for review and comment. Most relevant in this request is that it is the first 
request to deregulate a GE plant variety that is intended solely for the use in the production of 
ethanol. The corn variety is not cultivated for human consumption or livestock feed, but rather is 
grown to improve the efficiency of converting corn starch to industrial ethanol. A concern is that 
there is inadequate scientific data or documentation to evaluate the possible impacts on food and 
feed should this variety be commingled with commodity corn supplies.40 
GE Eucalyptus 
APHIS granted a permit on May 12, 2010, to import a GE eucalyptus tree that is “cold-tolerant.” 
If commercialized, the hybrid Eucalyptus would be used for pulp and biofuel production. 
Eucalyptus is a fast-growing tree that dominates tropical timber plantations. It is not native to the 
United States and has become invasive in some places. The permit was issued to a company 
called ArborGen, LLC. ArborGen is a joint initiative of International Paper, MeadWestvaco, and 
Rubicon. The permit authorizes planting and flowering on 28 sites across seven southern states 
(Alabama, Florida, Georgia, Louisiana, Mississippi, South Carolina, and Texas). The Center for 
Biological Diversity and other organizations have sued to set aside the approval on grounds that 
the potential environmental impacts have not been properly evaluated, nor has APHIS complied 
with congressional mandates enacted in the 2008 farm bill (P.L. 110-246) requiring more rigorous 
oversight of field testing for GE organisms.41  
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 Federal Register, vol. 74, 106, June 4, 2009, http://www.aphis.usda.gov/brs/fedregister/BRS_20090604b.pdf. 
40
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Global Trade Concerns 
The U.S. approach to biotechnology regulation contrasts with that of many major trading 
partners. For example, the European Union (EU), Japan, South Korea, New Zealand, and 
Australia either have or are establishing separate mandatory labeling requirements for products 
containing genetically modified ingredients; in many of these countries, consumer and official 
attitudes toward GE foods are more skeptical. Differing regulatory approaches have arisen at least 
partly because widely accepted international standards continue to evolve. Incidents, such as 
those discussed below, have disrupted U.S. exports and contributed to trade tensions.42 
GE Rice 
Although several GE varieties of rice have been approved for commercial use (“deregulated,” in 
regulatory parlance), none have been marketed, although they have been planted on test plots in 
the United States. In August 2006, the Secretary of Agriculture announced that “trace amounts” of 
an unapproved variety of GE rice had been found in samples of the 2005 crop of U.S. long grain 
rice. The Secretary and other USDA officials sought to reassure the rice trade and consumers that 
the findings posed no human health, food safety, or environmental concerns. 
Owner Bayer CropScience had not asked APHIS to deregulate this particular line, called 
LLRICE601, which had been field tested between 1998 and 2001. Two other Bayer GE rice 
varieties, known as LLRICE62 and LLRICE06, had received commercial approval but have not 
been commercialized, USDA stated. Also, “[t]he protein in LLRICE601 is approved for use in 
other products” and “has been repeatedly and thoroughly scientifically reviewed and used safely 
in food and feed, cultivation, import and breeding in the United States, as well as nearly a dozen 
other countries around the world.”43 
Nonetheless, the discovery unsettled rice markets and rekindled longtime criticisms of U.S. 
biotechnology regulatory policies. The U.S. rice crop is valued at nearly $2 billion annually. 
Exports represent approximately one-half or more of U.S. rice production annually on a volume 
basis, of which about 80% is long grain (the type in which GE material was detected), according 
to USDA statistics. Although the United States produces only about 1.5%-2% of the world rice 
crop, it was the fourth-leading exporter (behind Thailand, Vietnam, and India), with more than 
13% of world market share in 2005. 
Of the 4.4 million metric tons (MMT) exported in 2005, Mexico was by far the leading buyer, at 
753,000 MT. Japan was the second-leading market at nearly 424,000 MT. Various Central 
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 “Statement by Agriculture Secretary Mike Johanns Regarding Genetically Engineered Rice,” August 18, 2006. LL 
stands for “Liberty Link,” a trademark name for the herbicide glyphosinate. LL crops are engineered to tolerate the 
herbicide, making for more effective weed control. 
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American and Caribbean countries took a total of 1.4 MMT; Iraq, 310,000 MT; and European 
Union (EU) countries, a total of 306,000 MT, USDA data show. Much of the long grain crop is 
produced in southern U.S. states, which generally ship from Gulf ports to Latin America, the 
Caribbean, and Europe, for example. California grows mainly medium and short grain rice 
varieties, which are marketed in Asia, including Japan. 
Following USDA’s notification that U.S. rice supplies had traces of GE material, September 2006 
closing rice futures dropped from $9.70 per cwt. (100 pounds) on August 18, closing at $8.99 per 
cwt. on August 25, 2005. (One year ago, the closing price was less than $7.00 per cwt.) The 
European Union (EU), which bought 279,300 MT of U.S. long grain rice in 2005, reacted by 
adopting a measure requiring all such shipments to be tested and certified as free of LLRICE601. 
Japan has indicated that it was suspending shipments of U.S. long grain rice although, as noted, 
most U.S. rice exports there are short and medium grain. 
According to a statement by the producer cooperative Riceland Foods, Inc., of Stuttgart, AR, the 
GE material was initially discovered by one of its export customers in January 2006. Riceland 
then sent a sample to a U.S. laboratory, which confirmed the Bayer GE trait, which is known to 
be present in (and approved for) corn, soybeans, canola, and cotton. Riceland said it collected 
samples from several storage locations in May 2006 and found positive results that were 
“geographically dispersed and random throughout the rice-growing area.” Bayer was notified in 
early June, and its tests confirmed the presence of the GE trait in the equivalent of 6 per 10,000 
kernels (0.06%).44 
In August 2006, USDA officials offered few additional details about the cause or extent of the 
problem. They indicated that they had not been informed by Bayer of the discovery until July 31, 
after which the Department began its own investigation, they stated. Among other actions, USDA 
said that APHIS was now moving to approve (i.e., deregulate) LLRICE601. Also, USDA’s Grain 
Inspection, Packers, and Stockyards Administration (GIPSA) has verified the use of two 
standardized tests that can test for the GE protein in rice shipments. 
Consumer and environmental advocacy groups were harshly critical of APHIS and USDA, noting 
that officials waited three weeks to make the discovery public—and still did not know where the 
samples were grown or how they entered the food supply. One group, the Center for Food Safety, 
subsequently called for a moratorium on all new field testing permits until oversight can be 
improved.45 In August 2006, rice farmers in Arkansas, Missouri, Mississippi, Louisiana, Texas, 
and California filed a class action lawsuit against Bayer CropScience, accusing the company of 
negligence in allowing unapproved genetically engineered rice to find its way into the 
commercial supply chain. By November 2006, APHIS declared the rice variety LLRICE601 safe 
for human consumption and deregulated the variety. USDA essentially declared that the new 
variety was similar to two Bayer varieties that had already been approved. 
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GE Wheat 
Trade concerns were apparent in the debate over whether to introduce (commercialize) a variety 
of glyphosate/Roundup-resistant wheat. Monsanto had asked the U.S. and Canadian governments 
for their approval, and other GE wheat varieties had been under development. Some producers 
wanted to plant the wheat as soon as it became available; others feared rejection by foreign 
customers of not only GE wheat, but all U.S. and Canadian wheat, out of concern that even non-
GE shipments might unintentionally contain some GE grain. The latter group wanted developers 
and regulators to wait for more market acceptance before releasing GE wheat varieties. 
In early 2003, a group of U.S. wheat producers petitioned the Administration to conduct a more 
thorough assessment of the environmental impacts of the Monsanto request; 27 farm, religious, 
and consumer advocacy organizations endorsed the petition in early 2004. Underlining these 
concerns, Japanese consumer groups in March 2004 reportedly told U.S. officials in wheat-
dependent North Dakota that their country would not import any U.S. wheat products if the 
Monsanto application was approved.46 
This resistance likely contributed to a decision by Monsanto to discontinue its efforts to win 
regulatory approval of a genetically modified wheat variety. Monsanto announced its decision in 
May 2004. Although Monsanto withdrew its applications for regulatory approval from EPA and 
APHIS, it did not withdraw its FDA application. FDA subsequently approved the application in 
July 2004. However, FDA approval alone is not sufficient to bring the GE wheat to market. 
While opposition to GE wheat remains strong among many U.S. trading partners, a spokesman 
for the joint biotechnology committee of the National Association of Wheat Growers and U.S. 
Wheat Associates, indicated in 2007 that support for planting and exporting GE wheat was 
growing among U.S some wheat producers.47 
In May 2009, wheat grower associations in the United States, Canada, and Australia issued a joint 
statement announcing that they intend to “work toward the goal of synchronized 
commercialization of biotech traits in our wheat crops.... [W]e believe it is in all of our best 
interests to introduce biotech wheat varieties in a coordinated fashion.”48 This joint statement 
produced an immediate reaction by various environmental and consumer organizations. Canada’s 
Farmers Union, the Organic Federation of Australia, the U.S. Organic Consumers Association, 
and other organizations drafted a statement opposing commercializing GE.49 In July, Monsanto 
Canada’s spokesperson stated that the future “GE wheat will not be Roundup ready.... It will have 
increased drought tolerance, increased yield, and improved nitrogen efficiency.”50 Monsanto 
anticipates that it will be at least 10 years before their research and development efforts produce a 
commercial variety of GE wheat. 
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U.S.-EU Dispute 
In May 2003, the United States, Canada, and Argentina initiated a complaint before the World 
Trade Organization (WTO) regarding the EU’s de facto moratorium on approvals of new GE 
crops. U.S. agricultural interests contended that the moratorium not only blocked exports such as 
corn and other products to the EU, but also was fueling unwarranted concerns about the safety of 
agricultural biotechnology throughout the world. The United States and its allies further argued 
that the EU moratorium was violating WTO rules stating that a country’s actions to protect health 
and the environment must be scientifically based, and approval procedures must be operated 
without undue delay. 
The WTO named a panel in March 2004 to consider the case. Although the EU effectively lifted 
the moratorium in May 2004 by approving a genetically engineered corn variety, the three 
complainants pursued the case, in part because a number of EU member states have continued to 
block approved biotech products. In February 2006, the WTO dispute panel, in its interim 
confidential report, ruled that a moratorium existed, that bans on EU-approved GE crops in six 
EU member countries (Austria, France, Germany, Greece, Italy, and Luxembourg) violated WTO 
rules, and that the EU failed to ensure that its approval procedures were conducted without 
“undue delay.” The final ruling was circulated to the parties in May 2006 and made public in 
September 2006. 
The dispute panel’s ruling dismissed several other U.S. and co-complainant claims, and did not 
address such sensitive issues as whether GE products are safe or whether an EU moratorium on 
GE approvals continued to exist. The final ruling, among other things, directed the EU to bring its 
practices in line with WTO rules. It concluded that the EU had breached its commitments with 
respect to 21 products, including types of oilseed rape, maize and cotton. It also said individual 
bans in Austria, France, Germany, Greece, Italy, and Luxembourg were illegal. 
The EU initially agreed on a November 2007 deadline for compliance with the WTO dispute 
ruling. The parties subsequently agreed to extend the time for EU compliance with the ruling to 
January 2008. The EU missed this deadline in large measure. Brussels has found it hard to 
implement the WTO ruling because some of the 27 EU member states operate their own bans on 
GE crops. Individual countries (e.g., Austria, France, Greece) have prohibited the sale or 
cultivation of certain EU-approved varieties of GE corn (e.g., MON810, a variety produced by 
Monsanto). In 2008, France also initiated a temporary national moratorium on GE crops. Spain 
continues to dominate the EU in GE crop cultivation. 
Although positive action has been slow, the United States has temporarily suspended WTO 
sanctions. U.S. agricultural interests, however, remain concerned that the stricter EU rules for 
labeling and tracing GE products will continue to discriminate against U.S. exports. If progress is 
not made, the issue is likely to return to the WTO’s dispute settlement body. The United States 
could retaliate against the EU to compensate for the annual value of lost U.S. exports, royalties 
and licensing fees to the EU from biotech crops. These could be levied by imposing extra tariffs 
on EU goods or lifting other WTO agreements regulating agriculture or health and safety. 
The WTO case did not involve the EU’s new “labeling and traceability” regulations, in effect as 
of April 2004, to require most food, feed, and processed products from GMOs to be labeled. GE-
based products also must be segregated from non-GE products, with documentation. U.S. 
agricultural interests argue that, even if the EU regularly approves GMOs, the labeling and 
traceability rules are themselves unworkable and unnecessary, and can mislead consumers by 
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wrongly implying that GM-derived products are inherently different than non-GM foods or pose 
safety concerns.51 The EU, however, continues to defend its mandatory labeling regime. 
At least one EU country, Germany, has addressed the issue of potential liability from GM crops—
passing a law in November 2004 that holds farmers who plant GM crops liable for damages to 
nearby non-GM fields (even if the GM farmers adhered to planting instructions and regulations). 
Some U.S. interests countered that the moratorium will not effectively end until the EU clears 
more of some two dozen or more GE food and agricultural products still awaiting regulatory 
approval—and EU member states actually implement the approvals. 
The Biosafety Protocol 
The Cartagena Biosafety Protocol, an outgrowth of the 1992 Convention on Biological Diversity 
(CBD), was adopted in January 2000 and took effect in 2003. The United States is not a party to 
the 1992 CBD, and therefore cannot be a party to the protocol. However, because its shipments to 
ratifying countries are affected, it has actively participated in the negotiations over the protocol 
text and in countries’ preparations for implementation. 
The protocol, which 134 other nations had ratified as of August 2006, permits a country to require 
formal prior notifications from countries exporting biotech seeds and living modified organisms 
(LMOs) intended for introduction into the environment. The protocol requires that shipments of 
products that may contain LMOs, such as bulk grains, be appropriately labeled and documented, 
and provides for an international clearinghouse for the exchange of LMO information, among 
other provisions. The Protocol further establishes a process for considering more detailed 
identification and documentation of LMO commodities in international trade. 
The United States objected to implementing measures approved during an international 
conference in Kuala Lumpur in February 2004. According to the United States, the measures 
would mandate overly detailed documentation requirements and potentially expose exporters to 
unwarranted liability damages if imported GMOs harm the environment or human health. U.S. 
government and industry officials believe that these and other rules could disrupt U.S. exports.52 
GMOs in the Developing World 
In Asia, particularly China and India, governments view GMOs as a way to produce more food 
for burgeoning populations, despite some in-country opposition and support for labeling GE 
products. China has been researching GE corn, cotton, wheat, soy, tomatoes, and peppers since 
1986. It has, however, been reluctant to approve commercial varieties of GE, which have been 
under development there. If so, it would be the first time a GE plant was used widely as a staple 
food, and may influence the decisions of other Asian countries with regard to accepting GE 
foods.53 
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In the debate over the potential contribution of biotechnology to food security in developing 
countries, critics argue that the benefits of biotechnology in such countries have not been 
established and that the technology poses unacceptable risks. They also suggest that intellectual 
property rights (IPR) protection gives multinational companies control over developing country 
farmers. Proponents say that the development of GE technology appears to hold great promise, 
with the potential to complement other, more traditional research methods, as the new driving 
force for sustained agricultural productivity in the 21st century. They maintain that IPR difficulties 
have been exaggerated.54 
According to a recent report published by the International Service for the Acquisition of Agri-
biotech Applications, 12 developing nations planted GE crops in 2007. Of the total 114.3 million 
hectares of GE crops cultivated worldwide, 43% of the global GE crop area is in developing 
countries. 
Differences on this issue were featured in 2002, when the United Nations (UN) World Food 
Program (WFP) announced an appeal for food aid to meet the needs of some 14 million food-
short people in six southern African countries: Lesotho, Malawi, Mozambique, Swaziland, 
Zambia, and Zimbabwe. However, a debate over the presence of genetically modified corn in 
U.S. food aid shipments made the provision of food aid more difficult and costly. Some of the 
countries expressed reluctance to accept unmilled GE corn on account of perceived 
environmental and commercial risks associated with potential introduction of GE seeds into 
southern African agriculture. Zambia refused all shipments of food aid with GE corn out of health 
concerns as well. In March 2004, Angola said it too would ban imports of GE food aid, including 
thousands of tons of U.S. corn, despite a need to feed approximately 2 million Angolans. 
The United States has blamed EU policies for southern African countries’ views on food aid 
containing GE products. The United States maintains that genetically modified crops are safe to 
eat and that there is little likelihood of GE corn entering the food supply of African countries for 
several reasons, including the fact that current bioengineered varieties of corn are not well 
adapted to African growing conditions. South Africa is the only African country to commercialize 
biotech crops. 
The Food and Agriculture Organization (FAO) of the United Nations has also offered a qualified 
endorsement of agricultural biotechnology, stating that it “can benefit the poor when appropriate 
innovations are developed and when poor farmers in poor countries have access to them.... Thus 
far, these conditions are only being met in a handful of developing countries.” Biotechnology 
research and development should complement other agricultural improvements that give priority 
to the problems of the poor, FAO said, adding: “Regulatory procedures should be strengthened 
and rationalized to ensure that the environment and public health are protected and that the 
process is transparent, predictable and science-based.”55 Other groups have been more pointed in 
criticizing GE crops, arguing that they can have hidden costs that are inadequately examined by 
biotechnology advocates.56 
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The Global Seed Industry 
Investments in crop variety research, including plant breeding, since the 1930s have led to 
tremendous growth in agricultural productivity. In the United States, corn productivity increased 
from 20 bushels per acre in 1930 to 140 bushels by the mid-1990s, a 600% increase. Much of this 
growth arose from innovations in major crop seeds, for example, hybridization. Such innovations 
have also led to further specialization in agriculture as commercial firms marketed elite crop lines 
developed in public land grant universities and agriculture experiment stations. This early 
specialization between the public and private research and development sectors has continued and 
accelerated, especially with innovations in plant genetic engineering and subsequent changes in 
intellectual property rights protection. Over the past 25-30 years, crop variety research and 
development has moved from a predominantly public activity to a largely private sector. Between 
1960 and 1996, private investment in crop varieties increased 14-fold in inflation-adjusted 
dollars, while public expenditure remained largely unchanged.57 
Seeds have distinct production processes and markets, but plant breeding, including genetic 
engineering and other biotechnologies, is the foundation of the seed industry today. Large, 
vertically integrated corporations now dominate the research and development, distribution, and 
marketing of seed varieties, although smaller companies may still operate under licensing and 
marketing agreements with the large firms. A new seed variety is typically contracted out to 
farmers and/or private firms for production and multiplication. Breeders provide growers with 
registered seed for large-scale production. Registered seed is then used to produce certified seed, 
which is sold commercially to farmers. Breeders closely manage contract growers to ensure that 
the desirable plant characteristics are retained in future seed generations. 
Certified seed is dried, cleaned, sorted, and packaged (“conditioned”) for sale. Under various 
state programs, the seed may be subjected to inspection to ensure quality. Large seed firms then 
market the seed to national and international markets. These firms may also license marketing to 
private firms to increase access to local markets. Distribution channels can differ depending on 
the region where the seed is marketed. For example, in the Midwest, most corn seed is sold 
through farmer-dealers trained by the seed company. In the South, corn seed is largely sold 
through agricultural supply firms. In addition, a large seed firm may sell directly to large farming 
operations. 
The Structure of the Seed Industry 
The global agribusiness sector has been undergoing consolidation and concentration for some 
time now. Through divestitures, mergers, and acquisitions, a few major integrated corporations 
currently dominate much of the agricultural input sector, (e.g., agricultural chemicals, seeds, and 
biotechnology traits). With the emergence of innovations in plant genetic engineering in the early 
1980s, an upsurge of takeovers and mergers began within the seed industry. Chemical and 
pharmaceutical industries were the major purchasers of independent seed companies. By 2005, 
                                                             
(...continued) 
accessed at http://www.centerforfoodsafety.org/pubs/FoE%20I%20Who%20Benefits%202008%20-
%20Full%20Report%20FINAL%202-6-08.pdf 
57
 Ferdandez-Cornejo, Jorge and David Schimmelpfennig. “Have seed industry changes affected research effort?” 
Amber Waves. Economic Research Service, USDA, February 2004. 
Agricultural Biotechnology: Background and Recent Issues 
 
Congressional Research Service 24 
according to Phillipps McDougall, a UK agribusiness consulting firm, the top 10 companies were 
estimated to comprise 51% of the world’s commercial seed sales.58 This figure is based on a 2005 
global seed market of $19.0 billion. A smaller group of transnational firms—Monsanto, 
DuPont/Pioneer, Syngenta—are the industry leaders today. Between 2004 and 2005, there was an 
increase in seed industry acquisitions. Monsanto, through its acquisition of Seminis in 2005, 
displaced Dupont/Pioneer as the world’s largest seed corporation (Table 2). 
Table 2. World’s Largest Seed Companies 
Company Seed Sales (Millions) 
Monsanto (United States) 
Dupont/Pioneer (United States) 
Syngenta (Switzerland) 
Group Limagrain (France) 
Land O’Lakes (United States) 
KWS AG (Germany) 
Bayer Crop Science (Germany) 
$6,700a 
$6,400 
$3,850 
$3,400 
$756 
$615 
$430 
Source: ETC Group, Communique #99: Patenting the “Climate Genes” ... and Capturing the Climate Agenda.” 
May/June 2008. 
a. Includes sales from Seminis, acquired by Monsanto in 2005, and Delta and Pine Land, acquired in 2007. 
Determining whether concentration and consolidation in the seed industry have reached a point 
where anti-competitive behavior becomes a concern requires accurate data on market share of 
individual firms and the total market value of the industry. Estimates for the size of the global 
seed market are not precise. According to one estimate, the 2006 global value of the commercial 
seed market was $22.9 billion. The International Service for the Acquisition of Agri-Biotech 
Applications (ISAAA) estimated the 2005 global market at $30 billion. In 2005, the International 
Seed Federation estimated the size of the market of seed and “other planting material” in 56 
counties at $25.2 billion. The ETC Group estimated the total to be $21 billion. Assuming a global 
seed market value of $21 billion, the top 10 firms (Table 2) dominated approximately 49% of the 
market in 2004-2005. 
The Herfindahl-Hirschman Index (HHI) is a measure of the size of firms relative to the overall 
industry and is an indicator of the degree of competition among them. As such, it is a simple 
measure of the degree to which a given market can be said to be competitive. The HHI is defined 
as the sum of the squares of the market shares of each individual firm. As the HHI decreases, it 
indicates a reduction in firm pricing power and an increase in competition. As the HHI increases, 
a few firms’ pricing power increases with a corresponding decline in market competition for the 
particular industrial sector. 
The Antitrust Division of the U.S. Department of Justice uses the HHI to determine whether a 
proposed merger would be anticompetitive (i.e., increase the pricing power of a few firms within 
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a sector). The HHI for the top four global seed firms is 393. The Antitrust Division considers an 
HHI of 1000-1800 to be moderately concentrated. An HHI of 1800 or more is a concentrated 
industry. 
Based on of the HHI, the global seed industry appears highly competitive. The simple HHI, 
however, can understate within-group concentration. While Monsanto, the largest seed company, 
has approximately 13%-14% of the global seed market, it has far greater dominance in particular 
seed categories. Monsanto’s Roundup Ready cotton, soybeans, and canola, for example, dominate 
the world’s genetically engineered (GE) crops, which have become an increasing share of global 
crop production.59 In 2004, Monsanto’s GE seed and/or its patented trait technology accounted for 
175.7 million acres, approximately 88% of the total global GE crop area.60 Monsanto has 41% of 
the global GE corn seed and 25% of global GE soybean seed sales.61 Table 3 shows Monsanto’s 
dominance of GE commodity crops. 
Table 3. Monsanto’s Global Share of Genetically Engineered Crops 
Crop Total Global GE Acreage Monsanto Share of Global GE Acreage 
GE Soybeans 
GE Corn 
GE Cotton 
GE Canola 
119.5 million acres 
47.7 million acres 
22.2 million acres 
10.6 million acres 
91% 
97% 
63.6% 
59% 
Source: ETC Group, Global Seed Industry Concentration –2005 
In addition to these bulk commodities, Monsanto has, with its 2005 acquisition of Seminis, 
become a dominant force in the vegetable seed market. Seminis supplies over 3,500 seed varieties 
to fruit and vegetable growers in 150 countries (Table 4). 
Table 4. Monsanto’s Share of Global Vegetable Seed Markets  
Vegetable Crop Global Share of Seed Market 
Beans 
Cucumber 
Hot Pepper 
Sweet Pepper 
Tomato 
Onion 
31% 
38% 
34% 
29% 
23% 
25% 
Source: ETC Group, Global Seed Industry Concentration –2005 
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Monsanto also announced in August 2006 its intention to buy Delta and Pine Land (D&PL), the 
world’s largest seed cotton company. Together, DP&L and Monsanto account for 57% of the 
United States cotton seed industry.62 DP&L has subsidiaries in 13 countries, including such major 
cotton producers as China, India, and Brazil. This proposed merger is under scrutiny by the 
Antitrust Division of the U.S. Department of Justice. 
ISAAA estimated the 2006 global market value of GE seeds was approximately $6.3 billion, 21% 
of the estimated global seed market of approximately $30 billion.63 Estimates of market value 
were based on the sale price of GE seed plus any applicable technology fees. ISAAA’s estimate of 
the distribution of GE crop market value was: 
• $2.68 billion for GE soybeans; 
• $2.39 billion for GE corn; 
• $0.87 billion for GE cotton; 
• $0.21 billion for GE canola. 
Anticompetitive Behavior 
Anticompetitive practices are business or government actions that prevent or reduce competition 
in particular markets. Such practices may include the creation of barriers to entry for firms, 
dumping of products on markets below their cost of production, price fixing, linking products 
together to limit consumer choice, government-granted monopolies, and other business actions. 
Anticompetitive practices are argued to have negative effects on markets and, by extension, 
whole economies, through the creation of monopoly profits. The assumption is that a free and 
efficiently functioning market economy arises when many enterprises, each with limited market 
power, are permitted to buy and sell. Such markets are then assumed to produce lower prices to 
consumers as well as a wider range of products. 
Some licensing practices and conditions pertaining to intellectual property rights may also 
restrain competition, have adverse effects on trade, and impede the transfer and dissemination of 
technology. Licensing practices or conditions that in particular cases constitute an abuse of 
intellectual property rights can have an adverse effect on competition in the relevant market. 
Governments enact competition laws to prevent these and other anticompetitive practices. The 
realities of modern competitive markets, however, are arguably sometimes more complex than 
simple theories of open market competition would suggest. Oligopolistic or quasi-monopolistic 
firms, for example, can achieve scale economies in production or marketing that would be 
difficult or impossible for smaller firms to accomplish. In these production sectors (e.g., airlines), 
the levels of capital investment are very high, and the firms’ evolution into quasi-monopolies can 
be an effective strategy from the standpoint of a competitive economy. 
This market dominance of GE seed noted above is reinforced by Monsanto’s U.S. dominance of 
glyphosate herbicide. In September 2006, a class-action suit involving 100,000 farmers was filed 
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against Monsanto, the world’s largest seed company, in the U.S. District Court in 
Wilmington, DE.64 Plaintiffs alleged that Monsanto, through its control of 80% of the U.S. market 
for glyphosate, had an effective monopoly. Monsanto has patents on seed lines of cotton, canola, 
and soybeans that are genetically engineered to be glyphosate tolerant. In their suit, the plaintiffs 
alleged that Monsanto retained product exclusivity “by acquiring seed companies that were 
developing modified seed technology, eliminating those products that could have led to the 
development of genetically modified seeds that could be used with non-glyphosate herbicide.” 
These efforts to block the development of competing genetically modified seeds had a direct 
effect on Monsanto’s glyphosate herbicide monopoly because had competing seeds been 
developed, farmers would have had a choice not only to buy competing seeds, but also to use 
different types of herbicides instead of glyphosate. Monsanto defeated the plaintiffs’ motion for 
class certification in July 2007; the case was dismissed without prejudice, and was refiled in the 
Missouri courts. 
The U.S. Department of Justice and USDA have announced dates and locations of joint public 
workshops that will explore competition and regulatory issues in the agricultural industry. The 
workshops, announced in August 2009 by Attorney General Eric Holder and Secretary of 
Agriculture Tom Vilsack, are the first joint USDA/Department of Justice workshops ever held to 
explore competition and regulatory issues in agriculture. Among the topics to be discussed is that 
of seed concentration. 
Contracts Between Seed Companies and Farmers 
Some criticism has arisen regarding the licensing arrangements between the corporate owners of 
seeds with novel traits and the farmers who plant the seeds. Because these licensing practices 
stem from the firms’ proprietary rights on the seed germplasm, those firms with large numbers of 
patents are often singled out for particular attention. While all firms have technology agreements 
with farmers who plant their seed, Monsanto has come under particular scrutiny for its 
technology agreement. Not only is Monsanto the world’s largest seed company, it also has the 
largest number of plant biotechnology patents (647 in 2003). Monsanto’s Technology Agreement 
gives the company significant control of the patented seed after the farmer has purchased, 
planted, and harvested the crop. If farmers fail to follow the terms of the agreement, they can be, 
and often are, the subject of enforcement actions brought by Monsanto. Even farmers who claim 
not to have knowingly planted genetically engineered seed can suffer financial penalties when 
their seed is found to contain Monsanto’s patented genetic material. Although seed source 
contamination is common, farmers who are discovered with Monsanto’s patented genetic material 
may find themselves in legal jeopardy.65 While these actions on the part of Monsanto have been 
the subject of much discussion and criticism, to date, they have not been challenged in the courts. 
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Other Selected Issues 
Food Safety and Labeling 
In the United States, many consumers may be wary of GE foods out of fear that introduced genes 
could prove allergenic, introduce increased toxicity, or otherwise be harmful to human health. 
Some critics express concern that FDA is placing all the responsibility on manufacturers to 
generate safety data, as it does normally under its pre-market approval system, and is reviewing 
only the conclusions of industry-sponsored studies, rather than conducting its own tests. They 
also believe that the process lacks transparency and adequate public scrutiny of data. Others 
defend the current system. They counter that additional testing and oversight are unnecessary 
because all foods must meet the same rigorous federal safety standards regardless of whether or 
not they are genetically engineered. 
In July 2004, the Institute of Medicine and the National Research Council (IOM/NRC) of the 
National Academies of Science released a report generally supporting the proponents’ view. The 
IOM/NRC found that food safety should be assessed based on the composition of the altered food 
(e.g., whether it contains new compounds, unusually high levels of nutrients, or other significant 
traits) rather than how the food was produced (by genetic engineering or conventional methods). 
However, the IOM/NRC determined that the safety of modified foods should be assessed on a 
case-by-case basis and cautioned that scientists’ current ability to predict adverse consequences of 
genetic changes is limited.66 
U.S. policy also does not require GE-derived foods to be so labeled as long as they are 
substantially the same as their more conventional counterparts. Nonetheless, some consumer 
groups continue to seek mandatory labeling of all GE foods. These groups argue that U.S. 
consumers, like their EU counterparts, should have an opportunity to see all relevant information 
on a label so that they can make food choices based on their own views about its perceived 
quality or safety. The food industry generally opposes compulsory labeling. It contends that 
consumers might interpret GE labels as “warning labels” implying that the foods are less safe or 
nutritious than conventional foods, when the industry believes the preponderance of science 
indicates otherwise. The industry also has asserted that mandatory labeling would require 
development of a costly and possibly unattainable system to ensure that GE and non-GE foods 
remain segregated from the farm to the store, with no added benefit to the consumer. The industry 
has asserted that if consumers want to purchase GE-free products, the market will support a 
voluntary system, as exists for organic foods (where rules already prohibit GE foods from being 
called “organic”).67 
At the international level, the Codex Committee on Food Labeling in May 2006 agreed to 
continue work on draft guidelines for biotech labeling, which has been under discussion for 
approximately 10 years. Committee members asked a work group co-chaired by Norway, 
Argentina, and Ghana to examine member countries’ biotech labeling policies, their rationale, and 
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experiences, among other questions.68 Over the objections of the United States, Canada, and 
several Latin American countries, the Codex Committee will continue work on biotechnology 
labeling. At an April 2008 meeting of Codex in Ottawa, the EU, most Asian nations, and African 
countries defended their mandatory labeling regimes as necessary to protect consumers.69 
Adventitious Presence 
A related question is the definition of “mixing” and whether there should be a threshold de 
minimis amount of GE material permissible in non-GE material. “Adventitious presence” (AP) 
refers to any incidental appearance of very small amounts of foreign material in a commodity, 
food, or feedstuff. This can occur at any time during production, harvesting, storage, or 
marketing. Another related question is how to assess liability if such mixing does occur, or if GE 
plants prove harmful to the environment. For example, to what extent if any should biotechnology 
companies share liability with producers and others who use their products? 
Presently in the grain business, even shipments of the highest grades are permitted to contain 
some specified low levels of unwanted material, such as weeds, damaged kernels, and/or stems 
and leaves. Corn graded No. 1, for example, may contain up to 2% foreign material. As more 
crops and acreage are devoted to GE varieties, it becomes increasingly difficult, if not impossible, 
to avoid their trace presence in non-GE varieties. 
No internationally recognized standards have existed for what amounts, if any, of GE material 
should be permitted in a non-GE crop, especially if that crop or a food derived from it will be 
labeled as non-GE. In the absence of such standards, individual countries are establishing their 
own, often varying, AP thresholds. The lack of consistent, scientifically sound standards is 
confusing consumers and disrupting trade, the biotech industry has asserted. For example, the 
new EU regulation sets a tolerance level for non-GM foods, feeds, and processed products at 
0.9%. All products with more than 0.9% must be labeled as GM. U.S. agricultural interests 
consider the EU regulation in particular to be unworkable and discriminatory. EU officials 
counter that their standards not only are reasonable but also are being demanded by consumers. 
(See also “U.S.-EU Dispute,” above.) 
In its January 23, 2004, notice, APHIS asked for comments on if, and how, its regulations should 
address the LLP question for GE plant material. Questions include whether such presence should 
be exempt from regulation, what thresholds (levels) of low-level presence (LLP) might be 
acceptable, and under what conditions. Major grain and biotechnology industry organizations 
responded by urging the FDA, EPA and APHIS to establish a policy governing LLP. In March 
2007, APHIS published a Federal Register notice describing how the agency responds when LLP 
of regulated GE materials occur in commercial seed or grain that may be used for food or feed.70 
In the proposed APHIS regulation revisions discussed above, APHIS has proposed establishing 
criteria under which the occurrence of LLP may not be cause for agency remedial action. The 
new provision would permit APHIS to determine that a LLP event is non-actionable when the 
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criteria support the conclusion that the LLP is unlikely to result in the introduction or 
dissemination of a plant pest or noxious weed. 
Environmental Concerns 
Two main issues continue to drive the science and public debate on the environmental impacts of 
GMOs. One issue is the transfer of the introduced genes to wild plants and non-GM crops (i.e., 
gene flow from GE plants). The second issue concerns the indirect effects of the GE crops 
themselves on the local environment. Aside from the contamination issue to producers who do 
not want to plant GE crops, there is the concern that introduced genes can lead to herbicide and 
pesticide resistance in non-target species.71 There is mounting evidence that some weeds have 
begun to show resistance to glyphosate/Roundup. Several varieties of rye grass, Palmer amaranth 
(pigweed), common waterhemp, and giant ragweed are showing signs of resistance to glyphosate, 
in addition to the common ragweed.72 
Biotechnology advocates claim that GE crops offer environmental advantages over 
conventionally produced organisms. They note that the technology is more precise than 
traditional methods like crossbreeding. The latter methods transfer unwanted and unanticipated 
characteristics along with the desired new traits from one organism to another. Biotechnology 
also has made it possible to apply fewer and less toxic chemical herbicides and insecticides and to 
reduce soil tillage (thereby decreasing erosion and improving soil fertility), supporters of the 
technology assert. 
Critics counter that genetic engineering is not like traditional breeding. It creates crop and animal 
varieties that would not otherwise occur in nature, posing unpredictable risks to the environment 
(and to human health), they point out. Because they are living organisms, GE crops are difficult to 
control, greatly increasing the potential for escaping into the environment, crossbreeding with and 
overtaking wild species, and generally disrupting the natural ecosystem, critics believe. For 
example, GE, herbicide-tolerant seeds or pollen could inadvertently create “superweeds” that out-
compete cultivated or wild plants, critics argue. 
A 2002 NAS/NRC report stated that it could find no new distinctions between the types of 
environmental risks posed by GE plants and those posed by more conventionally bred crops (and 
that, in fact, there is a need to re-evaluate the potential environmental effects of the latter). The 
study concluded that the current APHIS regulatory system for biotechnology had improved 
substantially since it was first initiated and is more rigorous than the environmental oversight for 
other agricultural products and practices. The study did find areas of concern, including the need 
for greater transparency and public input into the regulatory process, and for more ecological 
monitoring after GE plants are approved and enter the marketplace. 
                                                             
71
 Australian farmers grow non-GE imadiazolone-tolerant canola and non-GE triazine-tolerant canola. It is possible that 
if GE glyphosate-tolerant canola and GE glufosinate ammonium-tolerant canola are introduced, contamination could 
result in canola plants being unintentionally bred to be resistant to all four chemicals, glyphosate, gluphosinate 
ammonium, triazine, and imadizolone. The canola plants would be considered a “super weed.”  
72
 “Glyphosate Resistant Weeds a Growing Concern,” Minnesota Farm Guide, April 25, 2008, at 
http://www.minnesotafarmguide.com/articles/2008/04/25/ag_news/production_news/pro11.txt. On July 28, 2010, the 
House Committee on Oversight and Government Reform’s Domestic Policy Oversight Subcommittee held a hearing on 
the emergence of herbicide resistant weeds, with a particular focus on glyphosate-resistant weeds. 
Agricultural Biotechnology: Background and Recent Issues 
 
Congressional Research Service 31 
A 2004 NAS/NRC report cited studies to conclude that some GE organisms are viable in natural 
ecosystems and can breed with wild relatives. The report urged developers of GE organisms to 
consider biological techniques such as induced sterility in order to prevent transgenic plants and 
animals from escaping into the environment. “Because no single bioconfinement method is likely 
to be 100% effective,” and because few are well-developed, such developers should create a 
redundant system by using more than one method of containment. The report called for more 
research to improve both containment methods and public confidence in regulation.73 In May 
2004, a separate report by University of Arizona and Texas A&M University researchers 
confirmed the spread of GE corn into a nearby field of non-GE corn.74 In September 2004, a team 
of researchers from the Environmental Protection Agency confirmed the spread of GE grass 
pollen to non-GE grass up to 13 miles away, much further than previous studies would have 
indicated.75 
Plant-Based Pharmaceuticals from Biotechnology 
Worldwide, hundreds of GE plants are under development for use as “factories” for 
pharmaceuticals (and other industrial compounds). Between 2004 and 2007 approximately 485 
acres in the United States were planted to regulated GE plants for filed testing of plants producing 
pharmaceuticals, industrial compounds, and value-added chemicals for human consumption or 
phytoremediation.76 None of these compounds has been commercialized to date. Pharmaceuticals 
might include, for example, vaccines or medicines for forms of cancer, infectious diseases, 
cardiovascular and nervous system diseases, metabolic disorders, and agents of biowarfare. 
A National Research Council Report in 2004 recognized that “biopharm crops pose a wholly 
different order” of environmental and human health risks.77 APHIS announced in 2007 that an 
environmental impact statement was being prepared for field trials of a transgenic sunflower that 
in engineered to produce human proinsulin, which tests have shown to be structurally, chemically, 
and functionally the same as pharmaceutical grade human insulin. 
Proponents believe plant-based pharmaceuticals will provide a far more cost-effective alternative 
to conventional pharmaceutical production, which now requires major investments both in large 
volumes of purified culture mediums and in manufacturing plants. Plant-based pharmaceuticals, 
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on the other hand, may be more easily incorporated into the existing agricultural infrastructure, 
providing a significant new source of farm income, they believe.78 
Critics are concerned about impacts on the food supply if crops like corn (the most widely planted 
U.S. crop, an intensively researched plant for biotechnology, and also an airborne pollinator) are 
“pharmed.” In 2002, for example, material from GE-altered corn plants that had been test-planted 
in a prior growing season in Nebraska for pharmaceutical use (for ProdiGene, Inc.) was 
inadvertently mixed with some 500,000 bushels of soybeans, which had to be quarantined by 
USDA to keep them out of the food supply. USDA officials observed that the soybeans never 
reached the food or feed supply, evidence that current regulatory oversight is effective. Some 
critics argue that GE plants producing pharmaceuticals and industrial compounds should be 
evaluated by criteria different from those used to evaluate crops intended for food. Others have 
argued that biopharm plants should not be food crops. 
Concerns persist among both consumer groups and the food manufacturing industry about 
producing GE plant-made pharmaceuticals in food crops. Some want 100% prevention systems in 
place before the first product is commercialized. Some of these groups suggest that only non-food 
crops should be used for GE plant-made pharmaceuticals, or that, at a minimum, pharmaceutical 
crops should be banned from agricultural areas where food and feed crops are produced. Other 
potential issues include whether manufacturers of plant-based pharmaceuticals will be able to 
maintain consistency in dosages and overall quality, and unanticipated environmental problems 
(e.g., threatening endangered species).79 
Responding to such concerns, APHIS published in the March 10, 2003, Federal Register a notice 
tightening permit conditions for its 2003 field tests of GE plants with pharmaceutical and 
industrial traits. The changes included (1) doubling the minimum distance allowed between 
traditional corn fields and test sites of pharmaceutical or industrial corn; (2) for all pharmaceutical 
crops (corn and other), doubling fallow zones around test sites; (3) restricting what can be grown 
on a test site and fallow zone in the next growing season; (4) using dedicated machinery (e.g., 
harvesters, planters) and storage facilities only for pharmaceutical production—adequate cleaning 
for other uses is no longer acceptable; (5) submitting for APHIS approval equipment cleaning and 
seed cleaning and drying procedures; (6) increasing APHIS field site inspections from one per 
season to five per season plus two visits the following year to look for any volunteer plants; (7) 
more record-keeping and training requirements. APHIS issued a letter on January 14, 2004, aimed 
at clarifying and updating its previous guidance on permits.80 The proposed APHIS revisions for 
regulating GE plants discussed above would put GE plants expressing pharmaceuticals or 
industrial compounds in a risk category where the engineered trait had a high potential for harm. 
It is not the highest risk category. APHIS equated the biopharmed plants with a poplar engineered 
to produce enzymes for heavy metal remediation.81 
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In early August 2006, a U.S. district court judge in Hawaii ruled that APHIS had violated the 
federal Endangered Species Act (P.L. 93-205) and the National Environmental Policy Act (P.L. 
91-190) because it had failed to consider potential impacts on endangered species and critical 
habitats prior to approving field trials for pharmaceutical corn on more than 800 acres throughout 
the Hawaiian Islands. The four companies issued the permits by APHIS were ProdiGene, 
Monsanto, Hawaii Agriculture Research Center, and Garst Seed. All of the companies’ plants 
used to make pharmaceutical crops had been harvested before the suit was filed and the 
companies stopped planting the crops under the permits. Spokesmen for both Syngenta, which 
subsequently bought Garst, and Monsanto, said at the time they no longer intend to pursue 
research into making drugs from plant crops. 
Emerging Policy Issues 
In the coming decade, several policy issues are likely to be at the center of attention by industry, 
consumer groups, and policy makers. From a general perspective, some of the issues revolve 
around managing the coexistence of traditional agricultural production with the increased 
presence of GE-based agricultural production. In some respects, the policy and regulatory issues 
may not be fundamentally new or different from the biotechnology issues of the past 20 years. 
Rather, certain issues may increase in importance as the industry matures and these longer-
standing regulatory issues take new forms. While not exhaustive, some of these issues might 
include: 
• evolving technologies, including the introduction of new “stacked trait” 
varieties—plant varieties with multiple genetically engineered traits—which is 
likely to increase; continuing development and the eventual commercialization of 
GE plant-based industrial and pharmaceutical output traits; oversight of second-
generation biotechnology traits such as improved nutritional qualities and 
resistance to environmental stress (e.g., drought); 
• transgenic animals and the food and industrial/pharmaceutical products derived 
from them; animal welfare concerns; 
• importation of GE products; 
• low-level presence of unapproved GE materials in food and feed products; 
• the adequacy of environmental impact assessments; 
• issues related to transparency and the participation in policy and regulatory issues 
by various stakeholders (e.g., consumers, religious groups, animal welfare 
activists); 
• compliance with existing and emerging regulatory structures in the United States 
and our trading partners; testing and measurement issues; traceability and 
labeling of GE products. 
As noted above, the evolution of herbicide-resistant weeds, especially those resistant to 
glyphosate, is a growing concern. As herbicide resistance increases among weed varieties, there 
could be increased reliance on herbicides that are less benign than glyphosate (e.g., dicamba, 2,4 
D). Biotechnology companies have begun engineering new plant varieties that are tolerant to 
these herbicides, or varieties where several herbicide-tolerant traits are “stacked” into a single 
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variety.82 The environmental effects of the increasing herbicide resistance and the resort to other 
herbicides may become policy issues as companies seek to commercialize these new varieties.  
In Congress 
Congress generally has been supportive of GE products, although some Members have expressed 
wariness about their adoption and concerns about how they are regulated. Over the past several 
years, legislative activity has been relatively subdued. Congress continues to fund a variety of 
biotechnology-related activities at USDA, primarily through regular annual appropriations. Most 
of the USDA spending for biotechnology related programs is for various types of research 
(mainly through the Department’s Agricultural Research Service and the Cooperative State 
Research, Education, and Extension Service). APHIS’s BRS budget in FY2009 was $16.4 
million. This was approximately $5 million more than in FY2008. Most of the increase supported 
APHIS’s Biotechnology Quality Management System, a new voluntary, audit-based compliance 
assistance program. For FY2010, the BRS budget was $13.0 million, and for FY2011 the 
estimated budget is $18.7 million. Other USDA agencies also have received lesser amounts for 
various biotechnology activities. 
Animal cloning, although not involving transgenic animals to date, has been an area of some 
interest. In the 111th Congress, Representative Fortenberry introduced H.R. 110, the Human 
Cloning Prohibition Act of 2009. Representative Kucinich introduced H.R. 5578, the Genetically 
Engineered Safety Act, which would prohibit open-air cultivation of GE pharmaceutical and 
industrial crops and the use of common human food or animal feed as the host plant for a 
genetically engineered pharmaceutical or industrial chemical. Representative Kucinich also 
introduced H.R. 5579, the Genetically Engineered Technology Farmer Protection Act. The bill 
would provide various legal protections for farmers and ranchers that may be harmed 
economically by GE seeds. The bill also would assign liability for injury caused by GE 
organisms. 
In the 110th Congress, Representative Kucinich also introduced the same bills he introduced in 
the 111th Congress: H.R. 6635, Genetically Engineered Safety Act; and H.R. 6637, Genetically 
Engineered Technology Farmer Protection Act. He also introduced H.R. 6636, Genetically 
Engineered Food Right to Know Act, which would require foods that contained GE material to be 
so labeled. 
In the 109th Congress, Members continued to follow trade developments, particularly the U.S.-
EU dispute, and GE rice case, as well as U.S. regulatory mechanisms for approving biotech 
foods. However, there were few proposed bills. In May 2006, Representative Kucinich again 
introduced a series of bills, like those he offered in the 108th Congress, to provide what he called 
“a comprehensive regulatory framework” for GE plants, animals, and other organisms. The bills 
were H.R. 5266, H.R. 5267, H.R. 5268, H.R. 5269, H.R. 5270, and H.R. 5271. 
In the 108th Congress, after the Administration launched a formal challenge of the EU GMO 
moratorium, the Senate on May 23, 2003, passed by unanimous consent a resolution (S.Res. 154) 
                                                             
82
 A new dicamba-resistant soybean is expected to be available as soon as 2013. See http://deltafarmpress.com/
dicamba-resistant-soybeans-2013. Dow AgroScience is currently developing a 2,4 D tolerant variety of corn. See 
http://www.dowagro.com/newsroom/corporatenews/2010/20100303a.htm. 
Agricultural Biotechnology: Background and Recent Issues 
 
Congressional Research Service 35 
in support of the action. A similar House measure (H.Res. 252) was passed on June 10, 2003, by a 
suspension vote of 339-80. Also in the 108th Congress, Representative Nick Smith introduced 
bills (H.R. 2447, H.R. 3472, H.R. 4651) to create an interagency task force to promote the 
benefits of agricultural biotechnology. Both bills were referred to the House Agriculture 
Committee, but no subsequent action was taken on them. Other members took a different 
approach in proposing bills related to food and agricultural biotechnology. 
Representative Kucinich introduced a series of bills during the 108th Congress (H.R. 2916, H.R. 
2917, H.R. 2918, H.R. 2919, H.R. 2920, H.R. 2921) that would have prescribed a variety of 
legislative changes intended to mandate labeling of GE-based foods, broaden FDA oversight, 
protect producers from any potential legal and environmental risks from agricultural 
biotechnology, prohibit unapproved U.S. exports of GE plants and animals, and tighten rules for 
producing and handling GE pharmaceutical and industrial crops, among other things. Senator 
Durbin introduced a bill, S. 2546, to require premarket consultation and approval for GE foods at 
the FDA. These bills were referred to various committees, but no further action was taken on 
them by the 108th Congress. 
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